Abstract 5P
Baseline tumor size (BTS) is a known predictor of response to anti-PD(L)1 immune checkpoint inhibitors (ICI) in melanoma and NSCLC patients (pts), with lower BTS predicting better treatment outcome. However, no data are currently available on the role of BTS in other solid tumors as well as for next-generation immuno-oncology agents (NGIO).
Resources from the same session
The exosomes transfer the acquired resistance of MCF-7 breast cancer cells to rapamycin and tamoxifen
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract
The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
Presenter: Ludovic Bourre
Session: Poster Display & Cocktail
Resources:
Abstract
The CellMiner and CellMinerCDB web-applications as a base for pharmacogenomics
Presenter: William Reinhold
Session: Poster Display & Cocktail
Resources:
Abstract
The application of radiomics-based machine learning in the differential diagnosis between atypical low-grade astrocytoma and anaplastic astrocytoma
Presenter: Manni Wang
Session: Poster Display & Cocktail
Resources:
Abstract
Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
Pharmacogenomics of docetaxel response in prostate cancer: A precision medicine initiative
Presenter: Abhinav Grover
Session: Poster Display & Cocktail
Resources:
Abstract
OX401, a new generation of PARP-interfering drug for cancer treatment
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract
Novel ERα degrader, 3,20(R)-dihydroxy-19-norpregnatriene, inhibits MCF-7 cell growth through p21/CDK2/CDK4 pathway
Presenter: Alexander Scherbakov
Session: Poster Display & Cocktail
Resources:
Abstract